<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04552990</url>
  </required_header>
  <id_info>
    <org_study_id>20-270</org_study_id>
    <nct_id>NCT04552990</nct_id>
  </id_info>
  <brief_title>Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma</brief_title>
  <official_title>Jet-Injection Assisted Photodynamic Therapy for Basal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether injecting ALA into the skin with a&#xD;
      jet-injection device and activating the drug with light is a safe treatment that causes few&#xD;
      or mild side effects in people with basal cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2020</start_date>
  <completion_date type="Anticipated">September 9, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evaluation of local skin responses on Day 0</measure>
    <time_frame>Day 1</time_frame>
    <description>Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 0 (PDT treatment #1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evaluation of local skin responses on Day 3</measure>
    <time_frame>Day 3</time_frame>
    <description>Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 3</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evaluation of local skin responses on Day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 14 (PDT treatment #2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evaluation of local skin responses on Day 17</measure>
    <time_frame>Day 17</time_frame>
    <description>Clinical evaluation of local skin responses on a 0-4 point scale will be performed at Day 17</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical evaluation of local skin responses 3 months post treatment</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>Clinical evaluation of local skin responses on a 0-4 point scale will be performed 3 months post treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>BCC</condition>
  <condition>BCC - Basal Cell Carcinoma</condition>
  <condition>Basal Cell Carcinoma</condition>
  <condition>Basal Cell Cancer</condition>
  <condition>Superficial Basal Cell Carcinoma</condition>
  <condition>Nodular Basal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tumor Excision, No Illumination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The first four patients will not receive illumination but have their tumors excised after jet-injection (AirGent2.0) of ALA (Levulan Kerastick), and 3h incubation; this will be done to assess biodistribution of ALA through fluorescence microscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PDT treatment with jet-injections</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient 5-16 will receive PDT treatment with jet-injections of ALA followed by 3h incubation under occlusion and thereafter illumination with red light (total dose 75 J/cm2). In patient 5-16, the PDT treatment will be repeated after 2 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jet injection of ALA</intervention_name>
    <description>The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).</description>
    <arm_group_label>PDT treatment with jet-injections</arm_group_label>
    <arm_group_label>Tumor Excision, No Illumination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgical excision</intervention_name>
    <description>In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).</description>
    <arm_group_label>PDT treatment with jet-injections</arm_group_label>
    <arm_group_label>Tumor Excision, No Illumination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Illumination</intervention_name>
    <description>For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).</description>
    <arm_group_label>PDT treatment with jet-injections</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Incubation</intervention_name>
    <description>After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).</description>
    <arm_group_label>PDT treatment with jet-injections</arm_group_label>
    <arm_group_label>Tumor Excision, No Illumination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who meet all of the following criteria are eligible to participate in this study&#xD;
&#xD;
          -  Histologically-verified, previously untreated low-risk mixed superficial and nodular&#xD;
             BCC or nodular BCCs &lt; 1 cm in diameter on scalp, extremities, or trunk.&#xD;
&#xD;
          -  â‰¥ 18 years of age&#xD;
&#xD;
          -  Owner of a smartphone (Android or iPhone). Patients without a working smartphone will&#xD;
             not be considered eligible for this study.&#xD;
&#xD;
          -  Being able to download application on their phone&#xD;
&#xD;
          -  Being able to take pictures of their treated BCC (with or without assistance)&#xD;
&#xD;
          -  Female subjects of childbearing potential must be confirmed not pregnant by a negative&#xD;
             urine pregnancy test prior to trial treatment. (Female subjects are considered of&#xD;
             childbearing potential unless they have been hysterectomized or have undergone tubal&#xD;
             ligation or have been post-menopausal for at least one year prior to the first visit)&#xD;
&#xD;
          -  Legally competent, able to give verbal and written informed consent&#xD;
&#xD;
          -  Subject in good general health and willing to participate comply with protocol&#xD;
             requirements.&#xD;
&#xD;
          -  Superficial and nodular BCC&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects meeting any one of the following criteria are not eligible to participate in this&#xD;
        study&#xD;
&#xD;
          -  High-risk BCC (H area, &gt;1 cm in M area, or &gt;2 cm in L area)&#xD;
&#xD;
          -  BCC subtype morpheaform&#xD;
&#xD;
          -  Diagnosed with gorlin syndrome&#xD;
&#xD;
          -  Receiving immunosuppressive medication&#xD;
&#xD;
          -  Subjects with a known allergy to ALA&#xD;
&#xD;
          -  Individuals with other interfering skin diseases in the area of treatment&#xD;
&#xD;
          -  Subjects with a tattoo in the treatment area which may interfere with or confound the&#xD;
             evaluation of the study&#xD;
&#xD;
          -  Subjects with a history of keloids which is deemed clinically relevant in the opinion&#xD;
             of the investigator&#xD;
&#xD;
          -  Lactating or pregnant women&#xD;
&#xD;
          -  Patient who are taking prescription pain medications or can not stop OTC pain&#xD;
             medications.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Rossi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Rossi, MD</last_name>
    <phone>646-608-2311</phone>
    <email>rossia@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Allan Halpern, MD</last_name>
    <phone>646-608-2328</phone>
    <email>halperna@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Rossi, MD</last_name>
      <phone>646-608-2311</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Superficial BBC</keyword>
  <keyword>Nodular BBC</keyword>
  <keyword>Superficial Basal Cell Carcinoma</keyword>
  <keyword>Nodular Basal Cell Carcinoma</keyword>
  <keyword>BCC</keyword>
  <keyword>Basal Cell Carcinoma</keyword>
  <keyword>PDT treatment</keyword>
  <keyword>photodynamic therapy</keyword>
  <keyword>Jet injection</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>20-270</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Basal Cell</mesh_term>
    <mesh_term>Neoplasms, Basal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

